P53 overexpression in colorectal metastases confined to the liver and outcome of liver resection

Hepato-Gastroenterology

Volumn 46, Issue 30, 1999, Pages 3109-3114

  Heisterkamp, Joos ^a   Van Bommel, Jasper ^a   Hop, Willebrordus CJ ^a   Tilanus, Hugo W ^b   Zondervan, Pieter E ^a   IJzermans, Johannes NM ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Colorectal carcinoma; Hepatectomy; Oncogen; Tumor suppressor gene

Indexed keywords

PARAFFIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; MALE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUESTIONNAIRE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENES, P53; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; PROGNOSIS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032786341     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. 1 Steele G, Jr: Hepatic metastasis resection: results. In: Morris DL, McArdle CS, Onik GM (Eds.). Hepatic metastases: diagnosis and management. Oxford: Butterworth-Heineman, 1996; pp. 57-66.
2. 2 Herfarth C, Kallinowski F: Can clinical assessment predict a patient's prognosis after liver metastasis. Ann Surg 1997; 226:581.
3. 3 Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C: Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996; 131:322-329.
4. 4 Middleton G, Cunningham D: Current options in the management of gastrointestinal cancer. Ann Oncol 1995; 6(Suppl 1):17-25. (Review)
5. 5 Hamilton JM: Adjuvant therapy for gastrointestinal cancer. Curr Opin Oncol 1994; 6:435-440. (Review)
6. 6 Hoops TC, Traber PG: Molecular pathogenesis of colorectal cancer. Hematology/Oncology Clinics of North America 1997; 11:609-633.
7. 7 Goh HS, Chan CS, Khine K, Smith DR: p53 and behaviour of colorectal cancer. Lancet 1994; 344:233-234.
8. 8 Magrisso IJ, Richmond RE, Carter JH, Pross CB, Gilfillen RA, Carter HW: Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas. Lab Invest 1993; 69:674-681.
9. 9 Poller DN, Baxter KJ, Shepherd NA: P53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997; 75:87-93.
10. 10 Watson AJ, Merritt AJ, Jones LS, Askew JN, Anderson E, Becciolini A, Balzi M, Potten CS, Hickman JA: Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996; 73:889-895.
11. 11 Pricolo VE, Finkelstein SD, Hansen K, Cole BF, Bland KI: Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 1997; 132:371-374.
12. 12 Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
13. 13 Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D: The 1993 Walter Hubert lecture: the role of the p53 tumor suppressor gene in tumorigenesis. Br J Cancer 1994: 69:409-416.
14. 14 Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991: 253:49-53.
15. 15 Jenkins JR, Rudge K, Chumakov P, Currie GA: The cellular oncogene p53 can be activated by mutagnesis. Nature 1985: 317:816-818.
16. 16 Cripps KJ, Purdie CA, Carder PJ, White S, Komine K, Bird CC, Wyllie AH: A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene 1994: 9:2739-2743.
17. 17 Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13:1009-1022.
18. 18 Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, Bosman FT: Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994: 57:634-637.
19. 19 Krishnadath KK, Tilanus HW, van Blankenstein M, Bosman FT, Mulder AH: Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 1995; 175:175-180.
20. 20 Couinaud C: Comps. Le foie. Etudes Anatomiques et Chirurgicales. Paris: Masson, 1957.
21. 21 Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312:1604-1608.
22. 22 Hall PA, Lane DP: P53 in tumour pathology: can we trust immunohistochemistry? Revisited! J Pathol 1994; 172:1-4.
23. 23 Bertorelle R, Esposito G, Del Mistro A, Belluco C, Nitti D, Lise M, Chieco-Bianchi L: Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995; 19:463-471.
24. 24 Yuen S, Chung LP, Luk ISC, Chan SY, Ho JWC, Wyllie AH: Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations. Br J Cancer 1997; 76:1610-1616.
25. 25 Kay EW, Barry Walsh CJ, Whelan D, O'Grady A, Leader MB: Inter-observer variation of p53 immunohistochemistry: an assessment of a practical problem and comparison with other studies. Br J Biomed Sci 1996; 53:101-107.
26. 26 Yang JL, Ow KT, Russel PJ, Ham JM, Crowe PJ: Higher expression of oncoproteisn c-myc, c-erB-2/neu, PCNA and p53 in metastasizing colorectal cancer than in nonmetastasizing cancer. Ann Surg Oncol 1996; 3:574-579.
27. 27 Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, Cohen AM: p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996; 14:2696-2701.
28. 28 Costa A, Doci R, Mochen C, Bignami P, Faranda A, Gennari L, Silvestrini R: Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol 1997; 15:2008-2014.
29. 29 Gutman M, Fidler IJ: Biology of human colon cancer metastasis. World J Surg 1995; 19:226-234.
30. 30 Finkelstein SD, Sayegh R, Christensen S, Swalsky PA: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71:3827-3838.
31. 31 Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-532.
32. 32 Kastrinakis WV, Ramchurren N, Maggard M, Steele G Jr, Summerhayes IC: K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 1995; 130:9-14.
33. 33 Kochhar R, Halling KC, McDonnell S, Schaid DJ, French AJ, O'Connell MJ, Nagorney DM, Thibodeau SN: Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer. Diagn Mol Pathol 1997; 6:78-84.
34. 34 Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249:912-915.
35. 35 Pocard M, Paradis V, Adam R, Reynes M, Bismuth H: Possible prognostic significance of p53 immunoreactive status of hepatic colorectal cancer metastases following surgical resection. Eur J Cancer 1998; 34:594-595.